Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach

The prognosis of advanced metastatic melanoma (American Joint Committee on Cancer (AJCC) stage IV) remains dismal with a 5‐year survival rate of 6–18%. In the present study, an integrated MALDI mass spectrometric approach combined with artificial neural networks (ANNs) analysis and modeling has been...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Proteomics. Clinical applications 2007-06, Vol.1 (6), p.605-620
Hauptverfasser:	Matharoo-Ball, Balwir, Ratcliffe, Lucy, Lancashire, Lee, Ugurel, Selma, Miles, Amanda K., Weston, Daniel J., Rees, Robert, Schadendorf, Dirk, Ball, Graham, Creaser, Colin S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers MALDI Mass spectrometry Melanoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!